We offer one of the only dedicated neuroendocrine tumor (NETs) programs in the country, with the combined expertise to treat both gastroenteropancreatic neuroendocrine tumors (GEP-NETs) and pheochromocytomas and paragangliomas (PHEOs). Our program is the first and only one of its kind, making us one of the top neuroendocrine cancer treatment centers in the region.
Expert Care from Penn’s Neuroendocrine Cancer Specialists
Neuroendocrine tumor treatment requires expert care from a team of cancer specialists, which is why people from throughout the region come to receive care for NETs at Penn Medicine’s Abramson Cancer Center. We develop personalized treatment plans that combine the expertise of our world-renowned specialists, from NET-specialized medical oncologists to experienced surgeons.
Azedra, the First-Ever FDA-Approved Nonsurgical Treatment for Rare Neuroendocrine Cancers
Recently, the US Food and Drug Administration (FDA) approved the first-ever non-surgical treatment for the rare neuroendocrine cancers, pheochromocytoma and paraganglioma. The approval was based largely on the results of the Penn-led trial involving 68 patients who benefitted from receiving at least one therapeutic dose of Azedra.
Read the news release about the FDA approval of Azedra.
If you or a loved one has a neuroendocrine tumor, you can find out if Azedra is a possible treatment option by calling 800-789-7366 (PENN).
Other Neuroendocrine Tumor Treatment Options
In addition to Azedra, we offer the following neuroendocrine cancer treatment options:
- Chemoembolization of the hepatic artery
- Chemotherapy and biologic therapies, such as hormone therapy and octreotide
- Debulking surgery, including liver resection
- Ethanol injection
- External-beam radiation therapy
- Laparoscopic cortical sparing surgery
- Liver-directed therapies
- Liver transplantation
- Local and local-regional excision
- Proton pump inhibitors (PPIs)
- Radiofrequency ablation
- Targeted therapy